Novadip Biosciences announced positive data from its Phase I/II clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003, in patients with severe bone non-union (BNU) of the lower limb following trauma.
Novadip Biosciences announced positive data from its Phase I/II clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003, in patients with severe bone non-union (BNU) of the lower limb following trauma.